Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
JIMD Reports · 2019-11 · 50 (1) · 9-19
DOI: 10.1002/jmd2.12052 ↗Kurz gefasst
Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 14.09.2019. Verfasst von Hetanshi Naik und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background
Erythropoietic protoporphyria (EPP) and X‐linked Protoporphyria (XLP) are rare photodermatoses presenting with severe phototoxicity. Although anecdotally, providers who treat EPP patients acknowledge their life‐altering effects, tools that fully capture their impact on quality of life (QoL) are lacking.
Methods
Adult patients with EPP/XLP were given four validated QoL tools: the Patient Reported Outcomes Measurement Information System 57 (PROMIS‐57), the Hospital Anxiety and Depression Scale (HADS), the Illness Perception Questionnaire Revised (IPQR), and an EPP‐Specific tool. All patients received the PROMIS‐57 while the HADS, IPQR, and EPP‐Specific tools were introduced at a later date. Associations between responses and clinical phenotypes were explored.
Results
Two hundred and two patients were included; 193 completed PROMIS‐57, 104 completed IPQR, 103 completed HADS, and 107 completed the EPP‐Specific tool. The IPQR showed that patients strongly believed EPP/XLP had a negative impact on their lives. Mean scores in anxiety and depression domains of both HADS and PROMIS‐57 were normal; however, anxiety scores from HADS were borderline/abnormal in 20% of patients. The EPP‐Specific tool revealed a decreased QoL in most patients. The PROMIS‐57 showed that 21.8% of patients have clinically significant pain interference. Several tool domains correlated with measures of disease severity, most being from the PROMIS‐57.
Conclusions
Impaired QoL is an important consequence of EPP/XLP. PROMIS‐57 was most sensitive in evaluating impaired QoL in EPP/XLP. Further research is needed to compare the effectiveness of it for assessing response to treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York.
- Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York New York.
- Department of Preventive Medicine and Community Health University of Texas Medical Branch Galveston Texas.
- Department of Medicine and Liver Center University of California San Francisco California.
- Department of Medicine University of Alabama Birmingham Alabama.
- Department of Medicine (Section on Gastroenterology & Hepatology) Wake Forest NC Baptist Medical Center Winston-Salem North Carolina.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Naik, H., Overbey, J. R., Desnick, R. J., Anderson, K. E., Bissell, D. M., Bloomer, J., Bonkovsky, H. L., Phillips, J. D., Wang, B., Singal, A., & Balwani, M. (2019). Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria. JIMD Reports, 50(1), 9-19. https://doi.org/10.1002/jmd2.12052
Vancouver
Naik H, Overbey JR, Desnick RJ, Anderson KE, Bissell DM, Bloomer J, et al. Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria. JIMD Reports. 2019;50(1):9-19. doi:10.1002/jmd2.12052
BibTeX
@article{Naik2019,
author = {Naik, Hetanshi and Overbey, Jessica R and Desnick, Robert J and Anderson, Karl E and Bissell, D Montgomery and Bloomer, Joseph and Bonkovsky, Herbert L and Phillips, John D and Wang, Bruce and Singal, Ashwani and Balwani, Manisha},
title = {Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria},
journal = {JIMD Reports},
year = {2019},
volume = {50},
number = {1},
pages = {9--19},
doi = {10.1002/jmd2.12052}
}
EUVIMED